Skip to Main Content

Author Details

Bora Lim
The University of Texas MD Anderson Cancer Center
2007
101
30
PMIDPaper TitleJournal TitlePublished Year
36900406Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients.Cancers (Basel)2023
37146584Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal.Cell Stem Cell2023
37043123Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.Invest New Drugs2023
37329887Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation.Cell Metab2023
35294223Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.JCO Precis Oncol2022
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
35860831Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer.Ther Adv Med Oncol2022
35413951Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.Nat Commun2022
36322628Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.Sci Transl Med2022
35267631Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.Cancers (Basel)2022
35113355Targeting Apoptosis in Cancer.Curr Oncol Rep2022
32984932A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.Invest New Drugs2021
33826739SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme.Radiat Res2021
33762732Breast tumours maintain a reservoir of subclonal diversity during expansion.Nature2021
33736924High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.Ann Oncol2021
33820779Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.Clin Cancer Res2021
33870112Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.Eur J Breast Health2021
33845027Inflammatory breast cancer: early recognition and diagnosis is critical.Am J Obstet Gynecol2021
33861773Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.PLoS One2021
33523229PD-L1 in Breast Cancer: The Road to the Perfect BiomarkerIs Fraught With Uncertainty.J Natl Cancer Inst2021
34676056Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.Oncotarget2021
34518211Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.Cancer Res2021
34686316Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility.Mol Cell2021
34680527ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.Biomedicines2021
34363799Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma.Hum Pathol2021
34203351PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.Biomedicines2021
34253579Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Clin Cancer Res2021
31924662Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy.BMJ Support Palliat Care2021
33140515A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.Oncologist2021
33403525The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.Ann Surg Oncol2021
32972830First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.Clin Colorectal Cancer2021
32289270Advancing Cancer Research and Medicine with Single-Cell Genomics.Cancer Cell2020
33842000Update on systemic treatment for newly diagnosed inflammatory breast cancer.J Adv Res2020
32061834Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled Trial.J Pain Symptom Manage2020
31731960Deglycosylation patterns of isoflavones in soybean extracts inoculated with two enzymatically different strains of lactobacillus species.Enzyme Microb Technol2020
32003919Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.Oncologist2020
31849202Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.Cancer Med2020
33114311Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer.Cancers (Basel)2020
33180796Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.PLoS One2020
32883032Targeting Signaling Pathways in Inflammatory Breast Cancer.Cancers (Basel)2020
32710271Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?Ann Surg Oncol2020
32958928Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis.Nat Immunol2020
32353087Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.PLoS One2020
32295530Design of PCR assays to specifically detect and identify 37 Lactobacillus species in a single 96 well plate.BMC Microbiol2020
31137625Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.Cancers (Basel)2019
31351155HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.Hum Pathol2019
31370269Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox.Cancers (Basel)2019
30777332Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer.Biochem Biophys Res Commun2019
31097774A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.Br J Cancer2019
30982934Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.Breast Cancer Res Treat2019
  • 1 - 50 of 101

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 1
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 1
Yin Liu
Fudan University Shanghai Cancer Center
Career Start Year 2011
Number of shared co-authors 1
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 1
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 1
Bo Gao
Crown Princess Mary Cancer Centre, Westmead Hospital
Career Start Year 2008
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 6
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 0
Naoto Kondo
Nagoya City University Graduate School of Medical Sciences
Career Start Year 2006
Number of shared co-authors 0
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 4
Sara M Tolaney
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Jeong Eon Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 3
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 4
Matthew P Goetz
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 2
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 6
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 3
Wei Zhang
Children's Hospital, Zhejiang University School of Medicine
Career Start Year 2001
Number of shared co-authors 2
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 4
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 4
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 8
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 5
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 1
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 1
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 3
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
Eric P Winer
Dana-Farber Cancer Institute
Career Start Year 1985
Number of shared co-authors 9
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 0
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 3

Collaborators

Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 45
James M Reuben
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
Gabriel N Hortobagyi
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Yu Shen
Co-authored papers 6
William F Symmans
Co-authored papers 5
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 5
Arvind Rao
University of Michigan-Ann Arbor
Co-authored papers 4
Kenneth R Hess
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Joshua E Allen
Co-authored papers 4
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Mien-Chie Hung
Co-authored papers 3
Abenaa M Brewster
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Liuqing Yang
University of Tennessee Health Science Center
Co-authored papers 2
Youqiong Ye
Co-authored papers 2
Angela Alexander
University of Texas MD Anderson Cancer Center
Co-authored papers 2
Neel S Madhukar
Weill Cornell Medical College
Co-authored papers 2
Powel H Brown
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Gautam Borthakur
MD Anderson Cancer Center
Co-authored papers 2
Sharon H Giordano
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Olivier Elemento
Meyer Cancer Center
Co-authored papers 2
Fahd Al-Mulla
Dasman Diabetes Institute
Co-authored papers 2
Peter Van Loo
The Francis Crick Institute
Co-authored papers 2
Sahil Seth
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Cyril H Benes
Co-authored papers 2
Simona F Shaitelman
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 1
Xiao Zhao
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Jonas Demeulemeester
VIB-KU Leuven Center for Cancer Biology
Co-authored papers 1
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Massimo Cristofanilli
Weill Cornell School of Medicine
Co-authored papers 1
Release 1.2